Combination therapy of ceftaroline with carbapenems restores antimicrobial activity by targeting PBP2a, suppressing resistance and virulence gene expression, and enhancing immune-mediated killing
Target Population
Patients with difficult MRSA infections, including bacteremia and biofilm-associated infections resistant to standard therapies
Care Setting
Hospital and clinical settings managing persistent or resistant MRSA infections
Key Highlights
Ceftaroline resistance in MRSA is emerging due to mecA and PBP mutations, threatening β-lactam treatment options.
Combination of ceftaroline with carbapenems (ertapenem or meropenem) shows in vitro synergy and restores activity against ceftaroline-resistant MRSA.
Murine bacteremia models demonstrate that ceftaroline–carbapenem therapy reduces bacterial burden effectively, supporting further clinical investigation.
Guideline-Based Recommendations
Diagnosis
Use broth microdilution antimicrobial susceptibility testing under standard and high inoculum conditions to identify ceftaroline-resistant MRSA.
Perform checkerboard assays to assess antibiotic interactions and synergy in resistant isolates.
Management
Consider combination therapy of ceftaroline plus carbapenems for ceftaroline-resistant MRSA infections.
Administer ceftaroline fosamil and carbapenems at clinically relevant dosing intervals as demonstrated in murine models.
Monitoring & Follow-up
Monitor bacterial load reduction through CFU enumeration in clinical samples to assess treatment efficacy.
Observe for potential toxicity and therapeutic response during combination antibiotic therapy.
Risks
Emergence of ceftaroline resistance due to mecA and PBP mutations.
Potential for suboptimal activity of monotherapy with vancomycin or daptomycin in high-burden or biofilm-associated MRSA infections.
Patient & Prescribing Data
Patients with persistent or high-burden MRSA infections exhibiting ceftaroline resistance
Combination therapy with ceftaroline and carbapenems restores antimicrobial activity and suppresses resistance mechanisms, suggesting improved outcomes over monotherapy.
Clinical Best Practices
Employ combination antibiotic therapy for ceftaroline-resistant MRSA to enhance bactericidal activity and suppress resistance.
Use in vitro susceptibility testing and synergy assays to guide antibiotic selection in resistant MRSA cases.
Apply dosing regimens validated in preclinical models, such as ceftaroline fosamil 12 mg/kg every 8 hours with ertapenem 100 mg/kg every 8 hours, pending clinical trial confirmation.
by Joshua Olson, Valliammai Alaguvel, Gabriel Pérez-Parra, Allen Jankeel, Anuj K Khetarpal, Valeria Rodríguez-Guevara, Vanessa Vu, George Sakoulas, Erlinda R Ulloa
